Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2020) 70 AEP797 | DOI: 10.1530/endoabs.70.AEP797

ECE2020 Audio ePoster Presentations Reproductive and Developmental Endocrinology (79 abstracts)

Ovarian reserve and serum concentration of thyroid peroxidase antibodies in euthyroid women with different polycystic ovary syndrome phenotypes

Agnieszka Adamska 1 , Agnieszka Lebkowska 2 , Anna Krentowska 2 , Justyna Pliszka 1 , Marcin Adamski 3 , Monika Leśniewska 4 & Irina Kowalska 2


1Medical University of Białystok, Department of Endocrinology, Diabetology and Internal Medicine, Poland; 2Medical University of Białystok, Department of Internal Medicine and Metabolic Diseases, Poland; 3Bialystok University of Technology, Faculty of Computer Science, Poland; 4Medical University of Białystok, Department of Reproduction and Gynecological Endocrinology, Poland


Objective: It has been shown that women with PCOS as well as with autoimmune thyroiditis (AIT), are characterized by increased incidence of infertility. Serum anti-Müllerian hormone (AMH), which reflects ovarian reserve, is elevated in PCOS women and is decreased in women with AIT. The Rotterdam criteria recognize four clinical PCOS phenotypes,i.e.,phenotype Acharacterized by clinical and/or biochemical hyperandrogenism (HA), menstrual dysfunction (oligo/amenorrhea) (Oligo) and polycystic ovarian morphology (PCOM), phenotype B (HA + Oligo), phenotype C (HA + PCOM) and phenotype D (Oligo + PCOM). To date, there is no study evaluating ovarian reserve and TPOAbs in different PCOS phenotypes. The aim of the present study was to investigate the relation between serum concentrations of TPOAbs and ovarian reserve in different PCOS phenotypes.

Patients and Methods: We examined 141 women with PCOS (phenotype A was diagnosed in 67 (47.5%) women, phenotype B in 30 (21.3%), phenotype C in 28 (19.9%), phenotype Din 16 (11.3%)) and 88 control subjects of similar age (P > 0.05). Physical examination was performed in all women. Serum concentration of LH, FSH, estradiol, total testosterone, AMH, TSH, thyroid hormones and TPOAbs were assessed and ultrasound of the ovaries was performed.

Results: Serum concentrations of TSH, fT4 and fT3 did not differ between the studied groups (all P > 0.05), all women were euthyroid. We observed positive serum TPOAbs in 31 (21.9%) women with PCOS and in 21 (23.9%) controls (P = 0.07). We did not observe differences in frequency of detection of positive serum TPOAbs between phenotype A (15 women, 22.4%), phenotype B (5 women, 16.7%), phenotype C (10 women, 35.7%) and control group (21 women, 23.9%) (P > 0.05). Interestingly, only one woman had positive serum TPOAbs (6.3%) in phenotype D. Serum AMH concentration was markedly higher in thewhole PCOS group (P < 0.01) and in phenotype A (P < 0.01) vs controls when serum concentration of TPOAbs was negative. However, in the groups with positive serum levels of TPOAbs, serum concentration of AMH did not differ between PCOS phenotypes and controls (all P > 0.05). We foundrelationships between serum TPOAbs concentrations and hip circumference (P = 0.03) and serum concentration of estradiol in the whole group (P = 0.002).

Conclusions: Frequency of serum detection of positive TPOAbs did not differ between PCOS phenotypeswith clinical/biochemical hyperandrogenism and control group, however, phenotype D is characterized by the lowest frequency of occurrence of positive TPOAbs. We observed differences in ovarian reserve between PCOS and control group with negative TPOAbs, whereas presence of TPOAbsabolished this differences.

Volume 70

22nd European Congress of Endocrinology

Online
05 Sep 2020 - 09 Sep 2020

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.